B7-1 and GM-CSF enhance the anti-tumor immune effect of DC-tumor fusion vaccine in the treatment of prostate cancer

Lian, Tong; Hao, Xiaodong; Li, Jianmin; Wang, Haitao; Li, Changying

doi:10.1007/s12032-020-01433-2

Cited by 7 publications

(3 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…demonstrated that mice inoculated with the FCs of DCs and mouse MC38 cells can induce the production of tumor-specific CTLs in vivo ( 22 ). Studies have demonstrated that DC/tumor FCs vaccine can induce tumor-specific immune response in a variety of tumors, including melanoma ( 23 ), acute myeloid leukemia ( 24 ), lung ( 25 ), prostate ( 26 ), liver ( 27 ) and breast cancer ( 28 ), in animal models or clinical trials.…”

Section: Introductionmentioning

confidence: 99%

Development of a Dendritic Cell/Tumor Cell Fusion Cell Membrane Nano-Vaccine for the Treatment of Ovarian Cancer

et al. 2022

View full text Add to dashboard Cite

Ovarian cancer (OC) is a malignant tumor that seriously affects women’s health. In recent years, immunotherapy has shown great potential in tumor treatment. As a major contributor of immunotherapy, dendritic cells (DCs) - based tumor vaccine has been demonstrated to have a positive effect in inducing immune responses in animal experiments. However, the effect of tumor vaccines in clinical trials is not ideal. Therefore, it is urgent to improve the existing tumor vaccines for tumor treatment. Here, we developed a fusion cell membrane (FCM) nano-vaccine FCM-NPs, which is prepared by fusing DCs and OC cells and coating the FCM on the poly (lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) loaded with the immune adjuvant CpG-oligodeoxynucleotide (CpG-ODN). The fusion process promoted the maturation of DCs, thus up-regulating the expression of costimulatory molecule CD80/CD86 and accelerating lymph node homing of DCs. Furthermore, FCM-NPs has both the immunogenicity of tumor cells and the antigen presenting ability of DCs, it can stimulate naive T lymphocytes to produce a large number of tumor-specific cytotoxic CD8+ T lymphocytes. FCM-NPs exhibited strong immuno-activating effect both in vitro and in vivo. By establishing subcutaneous transplanted tumor model, patient-derived xenograft tumor model and abdominal metastatic tumor model, FCM-NPs was proved to have the effect of delaying the growth and inhibiting the metastasis of OC. FCM-NPs is expected to become a new tumor vaccine for the treatment of ovarian cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Development of a Dendritic Cell/Tumor Cell Fusion Cell Membrane Nano-Vaccine for the Treatment of Ovarian Cancer

et al. 2022

View full text Add to dashboard Cite

show abstract

“…[49][50][51][52][53] Mature DCs can activate T cells in the tumor site and migrate to the lymph nodes to cross-prime T cells with the tumor antigens, thus promoting the generation of tumor-specific CD8+ effector T cells to induce systemic and long-term antitumor immunity. 54,55 Thus, OV therapy has promising potential in treating solid cancers. However, OV therapy shows only moderate benefits in the clinic.…”

Section: Tce Therapy Combined With Oncolytic Virus (Ov) Therapy Mobil...mentioning

confidence: 99%

“…OVs can not only selectively infect and replicate in tumor cells to kill them but also stimulate DC maturation and induce local inflammation 49–53 . Mature DCs can activate T cells in the tumor site and migrate to the lymph nodes to cross‐prime T cells with the tumor antigens, thus promoting the generation of tumor‐specific CD8+ effector T cells to induce systemic and long‐term antitumor immunity 54,55 . Thus, OV therapy has promising potential in treating solid cancers.…”

Section: The Latest Cd3‐tce Therapy Strategies To Overcome Solid Tumorsmentioning

confidence: 99%

CD3‐T‐cell‐engager (TCE) therapies to overcome solid tumors: Beyond BiTEs

Zhang

Guo

Wang

et al. 2022

MedComm – Biomaterials and Applications

View full text Add to dashboard Cite

CD3‐T‐cell‐engager (TCE) therapies, such as bispecific T‐cell engagers (BiTEs), have achieved extraordinary success in treating hematological malignancies and have shown therapeutic effects comparable with those of chimeric antigen receptor (CAR)‐T therapies. However, solid tumors are challenging to treat with TCE therapies due to tumor heterogeneity, limited tumor enrichment, an immunosuppressive tumor microenvironment (TME), a lack of pre‐existing tumor‐infiltrating lymphocytes (TILs), serious on‐target off‐tumor toxicity, and so forth. Thanks to the increased understanding of resistance mechanisms and novel technologies, the next generation of TCE therapies for solid tumors is emerging. We focus on summarizing the latest progress in CD3‐based TCE therapies and discussing the future perspective of TCE therapeutic strategies against solid tumors. This perspective highlighted novel multitarget TCE therapies that integrated multiple functionalities to enhance antitumor efficacy while minimizing off‐target toxicity. Furthermore, TCE therapies also could be rationally combined with other antitumor therapeutics, including oncolytic viruses, CAR‐T cells, and immune checkpoint blockade. Moreover, TCEs should not be limited to redirecting polyclone T cells to tumor cells. The development of novel TCEs to bridge T cells and other cells in the TME is also promising. This perspective motivates the development of the new TCE therapies strategy to broaden the armamentarium of CD3‐TCE therapies and overcome solid tumors.

show abstract

A self‐assembled, genetically engineered, irradiated tumor cell debris vaccine

Sun,

Hu,

Geng

et al. 2024

Exploration

View full text Add to dashboard Cite

Vaccine‐based therapeutics for cancers face several challenges including lack of immunogenicity and tumor escape pathways for single antigen targets. It has been reported that radiotherapy has an in situ vaccine effect that provides tumor antigens following irradiation, helping to activate antigen‐presenting cells (APCs). Herein, a new vaccine approach is developed by combining genetically engineered irradiated tumor cell debris (RTD) and hyaluronic acid (HA), termed HA@RTD. A cancer cell line is developed that overexpresses granulocyte‐macrophage colony‐stimulating factor (GM‐CSF). A hydrogel was developed by covalent conjugation of HA with RTD proteins that acted as a potent vaccine system, the effects which were probed with T cell receptor sequencing. The engineered vaccine activated antitumor immunity responses and prevented tumor growth in mice even with a single immunization. HA@RTD vaccine efficacy was also assessed in therapeutic settings with established tumors and in combination with immune checkpoint blockade.

show abstract

B7-1 and GM-CSF enhance the anti-tumor immune effect of DC-tumor fusion vaccine in the treatment of prostate cancer

Cited by 7 publications

References 34 publications

Development of a Dendritic Cell/Tumor Cell Fusion Cell Membrane Nano-Vaccine for the Treatment of Ovarian Cancer

Development of a Dendritic Cell/Tumor Cell Fusion Cell Membrane Nano-Vaccine for the Treatment of Ovarian Cancer

CD3‐T‐cell‐engager (TCE) therapies to overcome solid tumors: Beyond BiTEs

A self‐assembled, genetically engineered, irradiated tumor cell debris vaccine

Contact Info

Product

Resources

About